Baseline clinical characteristics on admission of total cohort and comparison between the regular BSA and small BSA groups
| . | Total cohort . | Regular BSA . | Small BSA . | P-value . |
|---|---|---|---|---|
| (n = 64) . | (n = 46) . | (n = 18) . | ||
| Age, years | 46.3 ± 14.7 | 48.7 ± 12.3 | 40 ± 18.5 | 0.0309 |
| Male, n (%) | 40 (62.5) | 38 (82.6) | 2 (11.1) | <0.0001 |
| Body mass index, kg/m2 | 21.2 ± 3.5 | 18.6 ± 2.5 | 22.2 ± 3.4 | 0.0002 |
| Body surface area, m2 | 1.64 ± 0.2 | 1.74 ± 0.18 | 1.38 ± 0.09 | <0.0001 |
| INTERMACS profile level | ||||
| 1 | 21 (32.8) | 15 (32.6) | 6 (33.3) | 0.62 |
| 2 | 23 (35.9) | 18 (39.1) | 5 (27.8) | |
| 3 | 20 (31.3) | 13 (28.3) | 7 (38.9) | |
| Purpose of LVAD | ||||
| Bridge to transplant | 60 (93.7) | 44 (95.7) | 16 (88.9) | 0.34 |
| Destination therapy | 4 (6.3) | 2 (4.3) | 2 (11.1) | |
| Aetiology | ||||
| DCM | 33 (51.5) | 24 (52.1) | 9 (50) | 0.059 |
| dHCM | 6 (9.4) | 5 (10.9) | 1 (5.6) | |
| ICM | 10 (15.6) | 9 (19.6) | 1 (5.6) | |
| Myocarditis | 3 (4.7) | 2 (4.4) | 1 (5.6) | |
| Others | 12 (18.8) | 6 (13) | 6 (33.3) | |
| Valvular disease | ||||
| Moderate or severe TR | 5 (7.8) | 4 (8.7) | 1 (5.6) | 0.66 |
| Moderate or severe MR | 11 (17.2) | 8 (17.4) | 3 (16.7) | 0.94 |
| Moderate or severe AI | 0 (0) | 0 (0) | 0 (0) |
| . | Total cohort . | Regular BSA . | Small BSA . | P-value . |
|---|---|---|---|---|
| (n = 64) . | (n = 46) . | (n = 18) . | ||
| Age, years | 46.3 ± 14.7 | 48.7 ± 12.3 | 40 ± 18.5 | 0.0309 |
| Male, n (%) | 40 (62.5) | 38 (82.6) | 2 (11.1) | <0.0001 |
| Body mass index, kg/m2 | 21.2 ± 3.5 | 18.6 ± 2.5 | 22.2 ± 3.4 | 0.0002 |
| Body surface area, m2 | 1.64 ± 0.2 | 1.74 ± 0.18 | 1.38 ± 0.09 | <0.0001 |
| INTERMACS profile level | ||||
| 1 | 21 (32.8) | 15 (32.6) | 6 (33.3) | 0.62 |
| 2 | 23 (35.9) | 18 (39.1) | 5 (27.8) | |
| 3 | 20 (31.3) | 13 (28.3) | 7 (38.9) | |
| Purpose of LVAD | ||||
| Bridge to transplant | 60 (93.7) | 44 (95.7) | 16 (88.9) | 0.34 |
| Destination therapy | 4 (6.3) | 2 (4.3) | 2 (11.1) | |
| Aetiology | ||||
| DCM | 33 (51.5) | 24 (52.1) | 9 (50) | 0.059 |
| dHCM | 6 (9.4) | 5 (10.9) | 1 (5.6) | |
| ICM | 10 (15.6) | 9 (19.6) | 1 (5.6) | |
| Myocarditis | 3 (4.7) | 2 (4.4) | 1 (5.6) | |
| Others | 12 (18.8) | 6 (13) | 6 (33.3) | |
| Valvular disease | ||||
| Moderate or severe TR | 5 (7.8) | 4 (8.7) | 1 (5.6) | 0.66 |
| Moderate or severe MR | 11 (17.2) | 8 (17.4) | 3 (16.7) | 0.94 |
| Moderate or severe AI | 0 (0) | 0 (0) | 0 (0) |
AI: aortic insufficiency; DCM: dilated cardiomyopathy; dHCM: dilated phase of hypertrophic cardiomyopathy; ICM: ischaemic cardiomyopathy; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LVAD: left ventricular assist device; MR: mitral regurgitation; TR: tricuspid regurgitation; VAD: ventricular assist device.
Baseline clinical characteristics on admission of total cohort and comparison between the regular BSA and small BSA groups
| . | Total cohort . | Regular BSA . | Small BSA . | P-value . |
|---|---|---|---|---|
| (n = 64) . | (n = 46) . | (n = 18) . | ||
| Age, years | 46.3 ± 14.7 | 48.7 ± 12.3 | 40 ± 18.5 | 0.0309 |
| Male, n (%) | 40 (62.5) | 38 (82.6) | 2 (11.1) | <0.0001 |
| Body mass index, kg/m2 | 21.2 ± 3.5 | 18.6 ± 2.5 | 22.2 ± 3.4 | 0.0002 |
| Body surface area, m2 | 1.64 ± 0.2 | 1.74 ± 0.18 | 1.38 ± 0.09 | <0.0001 |
| INTERMACS profile level | ||||
| 1 | 21 (32.8) | 15 (32.6) | 6 (33.3) | 0.62 |
| 2 | 23 (35.9) | 18 (39.1) | 5 (27.8) | |
| 3 | 20 (31.3) | 13 (28.3) | 7 (38.9) | |
| Purpose of LVAD | ||||
| Bridge to transplant | 60 (93.7) | 44 (95.7) | 16 (88.9) | 0.34 |
| Destination therapy | 4 (6.3) | 2 (4.3) | 2 (11.1) | |
| Aetiology | ||||
| DCM | 33 (51.5) | 24 (52.1) | 9 (50) | 0.059 |
| dHCM | 6 (9.4) | 5 (10.9) | 1 (5.6) | |
| ICM | 10 (15.6) | 9 (19.6) | 1 (5.6) | |
| Myocarditis | 3 (4.7) | 2 (4.4) | 1 (5.6) | |
| Others | 12 (18.8) | 6 (13) | 6 (33.3) | |
| Valvular disease | ||||
| Moderate or severe TR | 5 (7.8) | 4 (8.7) | 1 (5.6) | 0.66 |
| Moderate or severe MR | 11 (17.2) | 8 (17.4) | 3 (16.7) | 0.94 |
| Moderate or severe AI | 0 (0) | 0 (0) | 0 (0) |
| . | Total cohort . | Regular BSA . | Small BSA . | P-value . |
|---|---|---|---|---|
| (n = 64) . | (n = 46) . | (n = 18) . | ||
| Age, years | 46.3 ± 14.7 | 48.7 ± 12.3 | 40 ± 18.5 | 0.0309 |
| Male, n (%) | 40 (62.5) | 38 (82.6) | 2 (11.1) | <0.0001 |
| Body mass index, kg/m2 | 21.2 ± 3.5 | 18.6 ± 2.5 | 22.2 ± 3.4 | 0.0002 |
| Body surface area, m2 | 1.64 ± 0.2 | 1.74 ± 0.18 | 1.38 ± 0.09 | <0.0001 |
| INTERMACS profile level | ||||
| 1 | 21 (32.8) | 15 (32.6) | 6 (33.3) | 0.62 |
| 2 | 23 (35.9) | 18 (39.1) | 5 (27.8) | |
| 3 | 20 (31.3) | 13 (28.3) | 7 (38.9) | |
| Purpose of LVAD | ||||
| Bridge to transplant | 60 (93.7) | 44 (95.7) | 16 (88.9) | 0.34 |
| Destination therapy | 4 (6.3) | 2 (4.3) | 2 (11.1) | |
| Aetiology | ||||
| DCM | 33 (51.5) | 24 (52.1) | 9 (50) | 0.059 |
| dHCM | 6 (9.4) | 5 (10.9) | 1 (5.6) | |
| ICM | 10 (15.6) | 9 (19.6) | 1 (5.6) | |
| Myocarditis | 3 (4.7) | 2 (4.4) | 1 (5.6) | |
| Others | 12 (18.8) | 6 (13) | 6 (33.3) | |
| Valvular disease | ||||
| Moderate or severe TR | 5 (7.8) | 4 (8.7) | 1 (5.6) | 0.66 |
| Moderate or severe MR | 11 (17.2) | 8 (17.4) | 3 (16.7) | 0.94 |
| Moderate or severe AI | 0 (0) | 0 (0) | 0 (0) |
AI: aortic insufficiency; DCM: dilated cardiomyopathy; dHCM: dilated phase of hypertrophic cardiomyopathy; ICM: ischaemic cardiomyopathy; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LVAD: left ventricular assist device; MR: mitral regurgitation; TR: tricuspid regurgitation; VAD: ventricular assist device.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
